心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JACC：偿性心衰导管消融治疗或可行

2013-08-06 晓静 编译 cmt

房颤代偿性心衰导管消融JACC
关注

近期发表于《美国心脏病学会杂志》（J Am Coll Cardiol）的一项小型无对照研究表明，对心房颤动合并射血分数保留的心力衰竭（HFPEF）患者行药物或反复手术的复合治疗手段是有效和安全的。但尚需大型随机对照研究证实上述房颤患者导管消融治疗的获益情况。 该研究纳入74例代偿性HFPEF合并房颤行导管消融的患者。调查导管消融后无房颤可能性和窦性心律维持的相关因素

近期发表于《美国心脏病学会杂志》（J Am Coll Cardiol）的一项小型无对照研究表明，对心房颤动合并射血分数保留的心力衰竭（HFPEF）患者行药物或反复手术的复合治疗手段是有效和安全的。但尚需大型随机对照研究证实上述房颤患者导管消融治疗的获益情况。

该研究纳入74例代偿性HFPEF合并房颤行导管消融的患者。调查导管消融后无房颤可能性和窦性心律维持的相关因素。在基线水平和消融后12个月期间利用超声心动图评估左心室应变和应变率。

结果显示，在随访的34±16个月期间，无药物治疗的单次和多次手术成功率分别为27% （n=20）和45% （n=33）。多次手术和药物辅助治疗的成功率为73% （n=54）。随访期间无并发症发生。多变量Cox回归分析显示，房颤类型（除外长程持续性房颤）和无高血压与窦性心律维持独立相关（HR分别为1.81和0.49，P=0.04）。在随访期间，左室收缩指数和舒张指数仅在维持窦性心律的患者中有所改善。

Tomoko Machino-Ohtsuka; Yoshihiro Seo; Tomoko Ishizu; Akinori Sugano; Akiko Atsumi; Masayoshi Yamamoto; Ryo Kawamura; Takeshi Machino; Kenji Kuroki; Hiro Yamasaki; Miyako Igarashi; Yukio Sekiguchi; Kazutaka Aonuma.Efficacy, Safety and Outcomes of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction.J Am Coll Cardiol. 2013;():. doi:10.1016/j.jacc.2013.07.020div>

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853240, encodeId=a67f185324082, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Jan 08 05:55:00 CST 2014, time=2014-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324834, encodeId=97de1324834ec, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399581, encodeId=5a8c139958176, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421574, encodeId=e3d214215e426, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597707, encodeId=f94f159e707b7, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=)]
    2014-01-08 hbwxf

    #JACC#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1853240, encodeId=a67f185324082, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Jan 08 05:55:00 CST 2014, time=2014-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324834, encodeId=97de1324834ec, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399581, encodeId=5a8c139958176, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421574, encodeId=e3d214215e426, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597707, encodeId=f94f159e707b7, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=)]
    2013-08-07 12498568m50暂无昵称

    #ACC#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1853240, encodeId=a67f185324082, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Jan 08 05:55:00 CST 2014, time=2014-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324834, encodeId=97de1324834ec, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399581, encodeId=5a8c139958176, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421574, encodeId=e3d214215e426, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597707, encodeId=f94f159e707b7, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=)]
    2013-08-07 wjcjjian

    #导管消融#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1853240, encodeId=a67f185324082, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Jan 08 05:55:00 CST 2014, time=2014-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324834, encodeId=97de1324834ec, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399581, encodeId=5a8c139958176, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421574, encodeId=e3d214215e426, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597707, encodeId=f94f159e707b7, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=)]
    2013-08-07 xiangyuzhou972

    #消融#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1853240, encodeId=a67f185324082, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Jan 08 05:55:00 CST 2014, time=2014-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324834, encodeId=97de1324834ec, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399581, encodeId=5a8c139958176, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421574, encodeId=e3d214215e426, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597707, encodeId=f94f159e707b7, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Wed Aug 07 23:55:00 CST 2013, time=2013-08-07, status=1, ipAttribution=)]
    2013-08-07 zhishijing

    #消融治疗#

    0

相关资讯

CAE：房颤/房速或为CRT治疗效果欠佳的原因

心脏再同步化治疗（CRT）的疗效与术后患者CRT起搏的数量密切相关。目前对CRT术后未能CRT起搏的原因、各种原因的所占比例未做过很好的研究。 来自霍普金斯大学的Cheng A等研究者收集了2006年至2011年间，通过起搏器程控获得起搏器数据的CRT患者作为研究对象。使用自动算法对相关数据进行分析，将未能CRT起搏的原因分为十类。对完成分类队列中的部分数据进行人工矫正。共检索了80768名

CAFS 2013：Ensite Velocity系统在持续性房颤的消融治疗中的应用

    Ensite Velocity系统的高密度标测功能在持续性房颤的消融治疗中有较独特的优势,与以往的三维标测系统相比，Ensite Velocity系统的高密度标测功能(High Density Mapping， HDM)在持续性房颤消融中的特点，可以用三个字概括，即：准、精和快。具体如下：1）准，即准确。能在三维模型表面的定义范围内（如定义为离表面距离

Circ Arrhythm Electrophysiol:中等强度运动时的低心率和未来心房颤动（房颤）风险相关

　一项对健康中年挪威男性的长期前瞻性研究结果显示，中等强度运动时的低心率和未来心房颤动（房颤）风险相关。 　　研究7月21日在线发表于Circulation: Arrhythmia and Electrophysiology。 作者Irene Grundvold博士（挪威Oslo大学医院）等在文章中介绍，“我们发现6分钟运动负荷后心率未超过100 bpm的男性房颤风险显著增高。”对受试者的

房颤治疗中的硬终点的选择与评价

　　房颤的机制尚未完全阐明，其治疗还存在很多困惑。 　　房颤治疗策略  　　目前房颤治疗的策略主要包括：复律并维持窦性心律、控制心室率并抗凝治疗以预防血栓栓塞、预防房颤的发生、房颤病灶的根除等。从治疗方式上可以 分为药物治疗和非药物治疗两大类，非药物治疗主要涉及射频消融治疗、起搏器治疗、体内心房除颤器治疗、外科手术治疗，此外还有左心耳封堵术等。  　　经导管射频消融是当

Europace：房颤冷冻球囊消融术后房速发生的临床特征

自从心房颤动肺动脉触发学说被证实以来，越来越多的房颤患者通过环肺静脉隔离技术根治了房颤，然而目前环肺静脉射频消融技术采用逐点消融，其消融的成功率很大程度上取决于操作者的经验，而且非透壁的射频消融是术后发生房速的主要危险因素。因此近年来一些“单次”消融技术应用于临床，冷冻球囊消融术是其中之一，它被广泛应用于阵发性房颤的消融，其短期及中期消融的成功率不低于传统的射频消融术，然而关于冷冻球囊消融术后房速

Stroke：亚洲房颤患者服用达比加群卒中预防效果一致且安全性更佳

一项发表在今年6月份美国《卒中》杂志上的、基于 RE-LY研究的最新亚组分析显示，泰毕全（达比加群酯）可为亚洲房颤患者和非亚洲房颤患者提供一致性的受益。与总体试验结果保持一致的是，泰毕全150 mg相较华法林可降低亚洲房颤患者的卒中和全身性栓塞（包括缺血性卒中）的发生风险。两种剂量方案的泰毕全（150mg和110mg）均可明显降低亚洲患者的出血性卒中发生风险。接受泰毕全治疗的亚洲患者的大出血